25th week of 2013 patent applcation highlights part 59 |
Patent application number | Title | Published |
20130158073 | Methods Of Diminishing Co-Abuse Potential - Methods of diminishing or eliminating the co-abuse of a methylphenidate drug comprising identifying a patient or patient group suspected or likely to abuse said methylphenidate drug in combination with a substance known or suspected to give rise to l-ethylphenidate or psychotropic effect when ingested in the combination and making available to said patent or patient group said methylphenidate drug substantially free of l-threo methylphenidate. | 2013-06-20 |
20130158074 | SMALL VOLUME ORAL TRANSMUCOSAL DOSAGE FORMS CONTAINING SUFENTANIL FOR TREATMENT OF PAIN - Compositions, methods and systems for administration of small volume sufentanil-containing drug dosage forms to the oral mucosa of a subject are disclosed. | 2013-06-20 |
20130158075 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS - The present invention relates to heterocyclic compounds of formula 1, in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof. | 2013-06-20 |
20130158076 | Methylene Urea Derivatives - The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. | 2013-06-20 |
20130158077 | PHARMACEUTICAL COMPOSITIONS - The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis. | 2013-06-20 |
20130158078 | Heterocyclic Sulfone MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction - Heterocyclic sulfone compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction. | 2013-06-20 |
20130158079 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS - Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities. | 2013-06-20 |
20130158080 | METHODS FOR TREATING HYPERTENSION IN BLACK PATIENTS - The present invention relates to methods of treating hypertension in a black patient using a therapeutically effective amount of a combination of an angiotensin II receptor blocker and chlorthalidone. | 2013-06-20 |
20130158081 | CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID - The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay. | 2013-06-20 |
20130158082 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO - The disclosure relates to methods of managing blood sugar levels and compositions related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diabetes, insulin resistance, or hyperglycemia comprising administering to a subject diagnosed with, at risk of or exhibiting symptoms of diabetes, insulin resistance, or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I. | 2013-06-20 |
20130158083 | METAXALONE COCRYSTALS - The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of metaxalone. Disclosed herein are several new cocrystals of metaxalone, including: a 1:1 metaxalone adipic acid cocrystal, a 1:0.5 metaxalone fumaric acid cocrystal, a 1:1 metaxalone salicyclic acid cocrystal, a 1:0.5 metaxalone succinic acid cocrystal, and a 1:0.5 metaxalone maleic acid cocrystal. The therapeutic uses of these metaxalone cocrystals are described as well as therapeutic compositions containing them. | 2013-06-20 |
20130158084 | Pharmaceutical Composition Comprising Losartin For Treating or Preventing Statin BasedGrug-Induced Muscle Toxicity - A pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof, which is capable of treating or preventing side effects such as muscle toxicity caused by administering a statin-based lipid-lowering drug, and a pharmaceutical combination composition comprising a statin drug and a losartan drug as active ingredients are provided. The pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof provides an effect on treating or preventing muscle-related side effects caused by administration of a statin drug for treating hyperlipidemia, as well as an intrinsic pharmacological effect for treating or preventing hypertension. When administered along with a statin drug in sequence or co-administered at the same time with the statin drug, the pharmaceutical composition can exhibit an effect of effectively or significantly decreasing or preventing side effects such as muscle toxicity. | 2013-06-20 |
20130158085 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION - The invention relates a pharmaceutical composition comprising a combination of:
| 2013-06-20 |
20130158086 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION - The invention relates a pharmaceutical composition comprising a combination of:
| 2013-06-20 |
20130158087 | TG2 INHIBITORS AND USES THEREOF - Methods and compounds for treating cancer, dmg resistance and/or metastasis are described herein. These methods and compounds can inhibit the expression of aberrant TG2 expression and/or inhibit the binding of GTP to TG2, and thereby prevent the induction of epithelial to mesenchymal transition of cancer cells, and a stem cell-like phenotype. | 2013-06-20 |
20130158088 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY - The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin. | 2013-06-20 |
20130158089 | MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIa MODULATOR - Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I: | 2013-06-20 |
20130158090 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA - A compound of formula (I): | 2013-06-20 |
20130158091 | POLYMORPHS OF SAXAGLIPTIN HYDROCHLORIDE AND PROCESSES FOR PREPARING THEM - The invention provides polymorphs of Saxagliptin hydrochloride, processes for preparing polymorphs of Saxagliptin hydrochloride, and pharmaceutical compositions of polymorphs of Saxagliptin hydrochloride. | 2013-06-20 |
20130158092 | New Oral Formulation - The present invention relates to a pharmaceutical composition, in particular to a composition for administering active agents which are poorly soluble in aqueous media, and/or which are acid sensitive. | 2013-06-20 |
20130158093 | GPR 17 Agonists and Screening Assay - The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I. | 2013-06-20 |
20130158094 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE - Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described. | 2013-06-20 |
20130158095 | EML4-ALK FUSION GENE - The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene. | 2013-06-20 |
20130158096 | MIRNAS INVOLVED IN THE BLOOD BRAIN BARRIER FUNCTION - The current invention relates to use of particular nucleic acids for modulating (increasing or decreasing) blood-brain barrier function, and for use of such nucleic acids in treatment of conditions involving blood brain barrier function, including multiple sclerosis, HIV infection, Alzheimer's disease, Parkinson's disease, epilepsy, and so on. Also provided is an assay for identifying drugs useful in modulating blood brain barrier function. | 2013-06-20 |
20130158097 | COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-β, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-β, and SMAD2/3. | 2013-06-20 |
20130158098 | Alkenyl Substituted Cycloaliphatic Compounds as Chemical Inducers of Proximity - Methods of inducing proximity of chimeric molecules in a cell are provided. Aspects of the methods include contacting a cell with an amount of alkenyl substituted cycloaliphatic (ASC) inducer compound, e.g., abscisic acid, effective to induce proximity of first and second chimeric molecules. Also provided are compositions and kits for practicing various embodiments of the methods. Methods of the invention find use in a variety of different applications, including transcription induction applications. | 2013-06-20 |
20130158099 | Methods for Identifying Agents that Inhibit Cell Migration, Promote Cell Adhesion and Prevent Metastasis - Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that modulate ActRII signaling and cell adhesion. Agents are tested that modulate cell adhesion, detachment, invasion and viability. Agents that modulate the expression, phosphorylation, function and translocation of ActRII signaling pathway members also can predict agents that modulate cell adhesion, detachment, invasion and viability. The methods have utility in identifying agents that prevent cancer cell metastasis, wound dehiscence, aortic dissection and aid retina attachment and skin replacement and fertility. | 2013-06-20 |
20130158100 | INTRACELLULAR DNA RECEPTOR - Provided herein are methods of identifying and using compounds that modulate an AIM2 polypeptide-mediated immune response. Further provided herein are methods of treating disease comprising administering to a patient a compound that decreases expression of an AIM2 polypeptide. Further provided herein are methods of providing gene therapy to a patient comprising administering to the patient a gene therapy agent and a compound that decreases expression of an AIM2 polypeptide. In certain embodiments, a compound that decreases expression of an AIM2 polypeptide comprises an siRNA or an shRNA. | 2013-06-20 |
20130158101 | REGULATORS OF NFAT AND/OR STORE-OPERATED CALCIUM ENTRY - Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca | 2013-06-20 |
20130158102 | Compositions and Methods for Inhibiting Expression of a Gene from the JC Virus - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell. | 2013-06-20 |
20130158103 | Method of Tissue-Selective Targeted Gene Transfer - The present invention relates to methods of delivering a gene, such as a therapeutic gene, to a desired area of stroma of a cornea that involves removing the corneal epithelium and dehydrating the cornea. Certain aspects of the present invention relate to methods of treating corneal scarring by delivering a TGFβ-antagonizing gene packaged in a viral vector. | 2013-06-20 |
20130158104 | VECTORS AND SEQUENCES FOR THE TREATMENT OF DISEASES - The present invention provides new sequences, gene constructions, vectors and pharmaceutical compositions for the treatment of diseases and specially, for the treatment of mucopolysaccharidoses. | 2013-06-20 |
20130158105 | CONFORMATION-SELECTIVE NUCLEIC ACID INHIBITORS OF AMPA GLUTAMATE RECEPTORS - The present invention relates to novel nucleic acid ligands or aptamers that demonstrate potent and selective inhibition of the open-channel conformation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. | 2013-06-20 |
20130158106 | TOCOPHEROL DERIVATIVES AND METHODS OF USE - Tocol derivative compounds, compositions comprising these tocol derivatives and methods of using the tocol derivatives are provided herein. Specifically the tocol derivatives have a partially unsaturated hydrocarbon tail and are thus distinct from the tocopherols. The hydrocarbon tails do not have a trans carbon-carbon double bond in the second isoprene unit of the hydrocarbon tail and are distinct from the tocotrienols. The compounds are expected to allow improved interaction with the α-tocopherol transfer protein receptor than the tocotrienols and better bioactivity than the tocopherols. | 2013-06-20 |
20130158107 | NOVEL FLAVONOIDS AND USES THEREOF - The present invention provides novel flavonoids extracted from an alcohol extract of dehulled adlay seeds. The present invention also provides a process for the preparation of the flavonoid and a method for treating inflammation in a subject, which method comprises administering to said subject an effective amount of the flavonoid and a pharmaceutically acceptable carrier or excipient. | 2013-06-20 |
20130158108 | USES OF N-BUTYLIDENEPHTHALIDE IN TREATING A LIVER INJURY AND IMPROVING LIVER FUNCTION - Provided is a method for treating a liver injury such as fibrosis, cirrhosis and hepatitis as well as a method for restoring liver function in a subject, which includes administrating to the subject a therapeutically effective amount of n-butylidenephthalide having the formula (I) as an active ingredient, or a pharmaceutically acceptable salt of ester thereof: | 2013-06-20 |
20130158109 | RHENIUM COMPLEXES AND THEIR PHARMACEUTICAL USE - The present invention is directed to a rhenium complex of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is Se; Y is NH, O or S or is a methylene group; Z is halogen; m=0, 1, or 2 and p=0, 1, or 2, provided that m and p are both different from zero when Y is NH, O or S; n=3; R′ is a phenyl group or a group of general Formula —(CH | 2013-06-20 |
20130158110 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 2013-06-20 |
20130158111 | Compositions and Methods for Depleting Mutant p53 - The invention is directed towards methods of treating abnormal tissues in a subject or sensitizing an abnormal tissue to a chemotherapeutic agent. The methods comprise screening at least a portion of an abnormal tissue for at least one mutant form of p53 protein, and administering at least one isothiocyanate (ITC) to the subject or abnormal tissue if the abnormal tissue is positive for the at least one mutant form of p53. | 2013-06-20 |
20130158112 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION - A pharmaceutical composition for inhibiting amyloid beta peptide in a subject includes a compound having the formula (I): | 2013-06-20 |
20130158113 | METHODS AND COMPOSITIONS FOR TREATING BRAIN CANCER - The present invention provides methods and compositions for treating brain cancer by cyclohexenone compounds. | 2013-06-20 |
20130158114 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 2013-06-20 |
20130158115 | Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the | 2013-06-20 |
20130158116 | Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the | 2013-06-20 |
20130158117 | Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the | 2013-06-20 |
20130158118 | Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the | 2013-06-20 |
20130158119 | PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN - Pharmaceutical semi-solid composition of Isotretinoin An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle | 2013-06-20 |
20130158120 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2013-06-20 |
20130158121 | METHODS FOR TREATING VASOMOTOR SYMPTOMS USING GABA ANALOGS IN A GASTRIC RETENTIVE DOSAGE FORM - Methods for treating vasomotor symptoms associated with menopause are described. | 2013-06-20 |
20130158122 | EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists - A method of treating ocular hypertension, lowering intraocular pressure, pain or inflammation, comprising administering to a mammal a pharmaceutical composition of an EP | 2013-06-20 |
20130158123 | METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND STEATOHEPATITIS - A compound of Formula (I): | 2013-06-20 |
20130158124 | 1-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF MAST CELL MEDIATED DISEASES - The present invention relates to the treatment of an individual afflicted with mast cell mediated diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 2013-06-20 |
20130158125 | Treatment of CNS Disorders with trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 2013-06-20 |
20130158126 | CANNABINOID QUINONE DERIVATIVES - Cannabinoid quinone derivatives. The present invention refers to cannabinoid quinone derivatives to be used as medicaments, particularly as PPAR gamma (PPARg) agonists for treating diseases which etiology is based on an impaired PPARg function as transcription factor i.e. PPARg-related diseases. | 2013-06-20 |
20130158127 | TEA TREE OIL DERIVATIVES - Some embodiments comprise tea tree oil derivatives, and compositions and uses of same, which have decreased cytotoxic and irritating characteristics. | 2013-06-20 |
20130158128 | NATURAL, MULTIPLE USE AND RE-USE, USER SATURATED WIPES - The present invention relates to a wipe suitable for multiple re-use comprising a biopolymer matrix composition, said biopolymer matrix comprising from about 0.1% to about 40% of an essential oil, about 30% to about 95% of a biopolymer, and about 1% to about 50% of a carrier fluid wherein a limited amount of said essential oil can be released from said matrix composition when exposed to a liquid solution; and wherein an additional limited amount of said essential oil can be re-released repetitiously thereafter upon re-use with an additional exposure of a liquid solution to said wipe. | 2013-06-20 |
20130158129 | NATURAL, MULTIPLE RELEASE AND RE-USE COMPOSITIONS - A composition comprising a biopolymer matrix, said biopolymer matrix comprising from about 0.1% to about 40% of an essential oil, about 30% to about 95% of a biopolymer, and about 0% to about 50% of a carrier fluid wherein a limited amount of said essential oil can be released from said matrix composition when exposed to a liquid solution; and wherein an additional limited amount of said essential oil can be re-released repetitiously thereafter upon re-use with an additional exposure of a liquid solution. | 2013-06-20 |
20130158130 | POLYMER COMBINATIONS FOR COSMETIC PREPARATIONS - The invention comprises dermatological or cosmetic preparations comprising a triple combination of anionic polymer and two rheology modifying polymers which increase the viscosity of the preparation by at least 200% at a high shear rate and do not increase the viscosity at a low shear rate by more than 50%, thus imparting an improved sensory richness during spreading, in comparison to preparations without this combination. | 2013-06-20 |
20130158131 | SILK FIBROIN MATERIALS AND USE THEREOF - The present invention provides processes for producing porous silk fibroin scaffold material. The porous silk fibroin scaffold can be used for tissue engineering. The porosity of the silk fibroin scaffolds described herein can be adjusted as to mimic the gradient of densities found in natural tissue. Accordingly, methods for engineering of 3-dimensional tissue, e.g. bone and cartilage, using the silk fibroin scaffold material are also provided. | 2013-06-20 |
20130158132 | Formulation Solution Adapted To Prolong Plasma Times Of Drugs In Mammals Including Humans - The composition adapted to prolong the residence time of drugs in the circulating plasma of mammals including humans comprises the following: | 2013-06-20 |
20130158133 | METHOD OF TREATING CARBOHYDRATE RICH FOODS FOR REDUCING THEIR GLYCEMIC INDICIES - The production of starch containing products such as rice for use in a low glycemic diet as a carbohydrate substitute in diet preparations is disclosed. The preparation may be readily adjusted in form and taste with respect to aroma, texture, consistency, and flavor for utilization in a number of food preparation techniques including baking and frying. The method provides digestible starches from native and commercial starches by controlled heating and/or enzymatic processing and filtration of carbohydrates. | 2013-06-20 |
20130158134 | Use of a safe, green and biodegradable absorptive material in the construction of diapers, feminine hygiene and adult incontinence products and devices - A method of making absorbent core systems for the construction of absorbent articles such as baby care, feminine hygiene or adult incontinence products. The method essentially replaces the traditional synthetic acrylic acid polymer-based hydrophilic material mixed with wood pulp fiber in the absorbent core with a safer, green, biodegradable plant-based material. | 2013-06-20 |
20130158135 | Organogel Compositions Comprising Alkylated Aromatic Acids - Disclosed is a composition comprising an organogel which comprises: (a) an alkylated aromatic acid compound of the formula | 2013-06-20 |
20130158136 | APPARATUS AND METHOD FOR CONDUCTING A FISCHER-TROPSCH SYNTHESIS REACTION - In order to avoid fouling (precipitation of solid matter on cold surfaces) in heat-exchangers down-stream of the gas outlet of a Fischer-Tropsch reactor, the reactor gas stream containing hydrocarbon products that are solid at lower temperatures is fed into a liquid wash tank. Condensation of heavy oil in the liquid wash tank is effected by feeding an evaporable light oil into the liquid wash tank. Heavy oil is recovered as a bottom product from the liquid wash tank while a gaseous product is taken out of the liquid wash tank as the top product. The light oil is obtained from the wash tank top product. | 2013-06-20 |
20130158137 | INTEGRATED BIOPROCESSING FOR FUEL PRODUCTION - Systems and methods are provided for enhancing the integration of processes for recovering products from algae-derived biomass. The enhanced process integration allows for increased use of input streams and other reagents that are derived from renewable sources. This increases the overall renewable character of the products extracted from the algae-derived biomass. The process integration can include exchange of input streams or energy between an algae processing system and a system for processing non-algal biomass. One example of improving process integration is using oxygenates that are generated in a renewable manner as a reagent for enhancing the algae processing system. | 2013-06-20 |
20130158138 | INTEGRAL SYNTHESIS GAS CONVERSION CATALYST EXTRUDATES AND METHODS FOR PREPARING AND USING SAME - Methods for preparing integral synthesis gas conversion catalyst extrudates including an oxide of a Fischer-Tropsch (FT) metal component and a zeolite component are disclosed. The oxide of the FT metal component is precipitated from a solution into crystallites having a particle size between about 2 nm and about 30 nm. The oxide of the FT metal component is combined with a zeolite powder and a binder material, and the combination is extruded to form integral catalyst extrudates. The oxide of the FT metal component in the resulting catalyst is in the form of reduced crystallites located outside the zeolite channels. No appreciable ion exchange of FT metal occurs within the zeolite channels. The acid site density of the integral catalyst extrudate is at least about 80% of the zeolite acid site density. | 2013-06-20 |
20130158139 | PROCESS FOR PRODUCTION OF HYDROCARBONS WITH CATALYST CONDITIONING - A method for continuous production of hydrocarbons from synthesis gas in the presence of a cobalt-based catalyst which comprises a step of providing synthesis gas from a source ( | 2013-06-20 |
20130158140 | ANTI-REFLECTION COATING COMPOSITION AND PROCESS FOR PREPARING THE SAME - The present invention relates to an anti-reflection coating composition containing hollow particles, an adhesive, and a hydrophobic organic solvent, wherein the weight ratio of the hollow particles to the solids content of the adhesive is in the range of 1:2 to 1:20. The present invention also provides a method for producing the anti-reflection coating composition. | 2013-06-20 |
20130158141 | EXPANDED POLYOLEFIN CONTAINING POWDERED ACTIVATED CARBON - A pre-expanded polyolefin particle containing powdered activated carbon (PAC) and a pre-expanded polyolefin particle containing PAC and a sterically hindered amine ether flame retardant, as well as processes for preparing pre-expanded polyolefin particles. A process for producing the pre-expanded polyolefin includes providing polyolefin polymer granules containing powdered activated carbon; impregnating the polyolefin polymer granules with a volatile blowing agent in an aqueous suspension at a pressure of 5 to 50 bar and at temperatures of 100 to 170° C.; and decompression to atmospheric pressure. | 2013-06-20 |
20130158142 | HYBRID PHD/PMPO POLYOLS FOR POLYURETHANE FOAM APPLICATIONS - This invention relates to hybrid polymer polyols. These hybrid polymer polyols comprise the free-radical polymerization product of (A) a base polyol comprising (1) a polymer modified polyol selected from (a) dispersions of polyureas and/or polyhydrazodicarbonamides in a hydroxyl group containing compound and (b) polyisocyanate polyaddition polyols, and (2) optionally, a polyol having a functionality of 2 to 6 and an OH number of from 20 to 500; (B) optionally, a preformed stabilizer; and (C) one or more ethylenically unsaturated monomers, in the presence of (D) a free-radical polymerization initiator, and (E) optionally, a polymer control agent. The present invention also relates to a process for the preparation of these hybrid polymer polyols, foams prepared from these hybrid polymer polyols and to a process for the preparation of these foams. | 2013-06-20 |
20130158143 | THERMOPLASTIC RESIN FOAM, METHOD OF PRODUCING THE SAME, AND LIGHT REFLECTING MATERIAL USING THE SAME - A thermoplastic resin foam, having a bubble with an average bubble diameter of 10 μm or less in the inside thereof, in which wherein the thermoplastic resin foam is prepared by using and foaming a thermoplastic resin composition containing 0.25 to 2.5 part(s) by mass of a melt-type crystallization nucleating agent (B), with respect to 100 parts by mass of an amorphous thermoplastic resin (A). | 2013-06-20 |
20130158144 | SPRAYABLE WASTE RUBBER-BASED COATING - Surface coating composition, method and apparatus for coating a surface. The surface coating composition comprises a recycled rubber product, one or more binding agent and optionally one or more additional agent. | 2013-06-20 |
20130158145 | POLYURETHANE HAVING HIGH LIGHT REFRACTION - The present invention relates to the use of solvent-free low-monomer polyisocyanates based on araliphatic diisocyanates for the production of light- and weather-resistant polyurethane bodies having a high light refraction and low dispersion. | 2013-06-20 |
20130158146 | POLYISOCYANATE MIXTURES - The invention relates to novel solvent-free, monomer-depleted polyisocyanate mixtures, and to the use thereof for producing light-resistant and weather-resistant polyurethane bodies with high optical refraction and low optical dispersion. | 2013-06-20 |
20130158147 | HIGH MOLECULAR WEIGHT, RANDOM, BISPHENOL BASED COPOLY(PHOSPHONATE CARBONATE)S - Disclosed are random copoly(phosphonate carbonate)s with the high molecular weight and narrow molecular weight distribution exhibiting a superior combination of properties compared to prior art. | 2013-06-20 |
20130158148 | PHOTOSENSITIVE SILICONE RESIN COMPOSITION - Provided is a resin composition which gives a cured product of a photocurable resin having excellent crack resistance even when formed into a thick film, and capable of maintaining a low coefficient of linear thermal expansion, low thermal weight loss, and a low cure shrinkage. This photosensitive silicone resin composition comprises (A) a silica particle-containing condensation reaction product and (B) a photopolymerization initiator, and is characterized in that the silica particle-containing condensation reaction product (A) is a condensation reaction product of a polysiloxane compound (a) comprising a hydrolytic condensation product of one or more silane compounds represented by the following general formula (1): R | 2013-06-20 |
20130158149 | ACTIVE-ENERGY-RAY-CURABLE HOT-MELT URETHANE RESIN COMPOSITION, MEMBER FOR ELECTRONIC DEVICE, THE MEMBER INCLUDING THE RESIN COMPOSITION, AND PACKING - An active-energy-ray-curable hot-melt urethane resin composition contains a hot-melt urethane and an active energy ray polymerization initiator, the hot-melt urethane being obtained by converting more than 50% and 100% or less of the total number of isocyanate groups in an isocyanate group-terminated urethane prepolymer into terminal (meth)acryloyl groups by a reaction with hydroxyl groups in a reactive functional group-containing (meth)acrylic compound, the isocyanate group-terminated urethane prepolymer being obtained by reacting a polyisocyanate component with a polyol component that contains an aromatic polyester polyol containing a 2,2-dimethyl-1,3-propylene structure in its molecule in an amount of 90% by mole or more of a glycol component and a polyol other than the aromatic polyester polyol. The hot-melt urethane resin composition has excellent properties such as hot melting, rapid curability, a shape-retaining property after being applied, flexibility, durability, a property of adhering to a base, a low outgas property, mechanical strength, and flame retardancy. | 2013-06-20 |
20130158150 | MULTISTEP UV PROCESS TO CREATE SURFACE MODIFIED CONTACT LENSES - Medical devices having a wettable, biocompatible surface are described herein. Processes for producing such devices are also described. | 2013-06-20 |
20130158151 | GELS FROM POLYSTYRENE-BASED PHOTOINITIATORS - The invention provides a method for the manufacture of a gel precursor. The method comprising the steps of combining a polymeric photoinitiator of the general formula (I): with one or more gel-forming polymers and/or gel-forming monomers to form a matrix composition, and curing the matrix composition obtained in the first step by exposing it to UV radiation. The invention also relates to the gel precursor itself, a method for the manufacture of a hydrophilic gel, the hydrophilic gel itself and a medical device comprising or coated with said gel. | 2013-06-20 |
20130158152 | INTERPENETRATING POLYMER NETWORK AND METHOD FOR MAKING THE SAME - An interpenetrating polymer network includes CH | 2013-06-20 |
20130158153 | THERMAL TRANSFER FILM - A thermal transfer film and a method of manufacturing an OLED display, the thermal transfer film including a light to heat conversion layer, the light to heat conversion layer being formed of a composition including carbon black having an oil absorption number (OAN) of about 50 cc/100 gram to about 120 cc/100 gram and a mean particle size of about 40 nm to about 200 nm; and a binder. | 2013-06-20 |
20130158154 | COAGENT FOR FREE RADICAL CURING FLUOROELASTOMERS - Disclosed herein are curable compositions comprising a free radical curable fluoroelastomer, a free radical generating compound and an unsaturated metal compound coagent. Such compositions cure well, exhibit good (i.e. low) compression set resistance and process well (i.e. have reduced polymer viscosity compared to similar compositions not containing the unsaturated metal compound coagent). | 2013-06-20 |
20130158155 | COAGENT FOR FREE RADICAL CURING CHLOROROELASTOMERS - Disclosed herein are curable compositions comprising a chloroelastomer, a free radical generating compound and an unsaturated metal compound coagent. Such compositions cure well, exhibit good (i.e. low) compression set resistance and process well (i.e. have reduced polymer viscosity compared to similar compositions not containing the unsaturated metal compound coagent). | 2013-06-20 |
20130158156 | METHOD OF CONVERTING A POLYMERIZABLE COMPOSITION INTO THERMOPLASTIC POLYURETHANE OF IMPROVED YELLOWNESS INDEX AND ARTICLE OBTAINED BY THIS METHOD - Method of producing a thermoplastic polyurethane having a light stabilization useful for ophthalmic applications, comprising combining precursors of a polyurethane and at least one antioxidant, and incorporating therein, either before, during or after polymerization, at least one light stabilizer, said method being characterized in that the antioxidant is benzenepropanoic acid, 3(1,1-dimethylethyl)-4-hydroxy-5-methyl-1,1′-[1,2-ethanediylbis(oxy-2,1-ethanediyl)]ester and the light stabilizer is bis(1,2,2,6,6-pentamethyl-4-piperidinyl)-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]butylmalonate together with at least one additional component chosen from among phenol, 2-(5-chloro-2H-benzotriazole-2-yl)-6-(1,1-dimethylethyl)-4-methyl and 2,2′-methylenebis(6-(2H-benzotriazol-2-yl)-4-1,1,3,3-tetramethylbutyl)phenol). | 2013-06-20 |
20130158157 | COMPOSITE FILLER PARTICLES AND PROCESS FOR THE PREPARATION THEREOF - A process for the preparation of composite filler particles, comprising: (a) coating a particulate filler having a median particle size (D50) of from 1 to 1200 nm; (b) agglomerating the coated particulate filler, for providing a granulation of the coated particulate filler wherein the granulation contains the coated particulate filler particles whereby the at least one coating layer may be crosslinked by crosslinking groups obtained by reacting the reactive groups and optionally a further crosslinking agent. | 2013-06-20 |
20130158158 | Paste-Like Bone Cement - The present invention relates to a kit comprising at least two pastes, A and B. Paste A contains at least one monomer for radical polymerisation; and at least one barbituric acid derivative as polymerisation initiator. Paste B contains at least one monomer for radical polymerisation; and at least one heavy metal compound as polymerisation accelerator that is selected from heavy metal salts and heavy metal complexes. Paste B contains less than 0.01% by weight, relative to the total weight of paste B, of a peroxide; at least one of the pastes A and B contains-at least one filling agent that is poorly soluble or insoluble in the monomer for radical polymerization in either paste A or B respectively; and at least one of the pastes A and B contains at least one inorganic halide salt. | 2013-06-20 |
20130158159 | EPOXY-CONTAINING POLYSILOXANE OLIGOMER COMPOSITIONS, PROCESS FOR MAKING SAME AND USES THEREOF - The present invention relates to stable, zero or low VOC epoxy-containing polysiloxane oligomer compositions that provide for a high degree of chemical resistance to compositions containing organic resins, while at the same time, maintaining or improving the flexibility of these organic resin-containing compositions, to processes for preparing epoxy-containing polysiloxane oligomer compositions, and to uses in coatings, sealants, adhesives, and composites containing the same. | 2013-06-20 |
20130158160 | NON-IONIC ASSOCIATIVE THICKENERS CONTAINING CYCLOHEXYLOL ALKYLS, FORMULATIONS CONTAINING THEM AND THEIR USES - The present invention concerns new associative thickeners of the HEUR type (Hydrophobically modified Ethylene oxide URethane) whose hydrophobic monomer is based on alkyl cyclohexylols. These are new polyurethanes that significantly thicken an aqueous formulation with a low, medium and high shear gradient. The invention also concerns the compositions containing them and their uses in different formulations such as aqueous paints. | 2013-06-20 |
20130158161 | Polycarbonate Resin Composition with Mar Resistance and Scratch Resistance - A polycarbonate resin composition includes 100 parts by weight of a base resin composition including about 30 to about 50 wt. % of a polycarbonate resin (A), about 20 to about 40 wt. % of a modified acrylic copolymer (B), about 5 to about 10 wt. % of a rubber modified aromatic vinyl graft copolymer (C), and about 10 to about 30 wt % of polybutylene terephthalate resin (D); and about 1 to about 8 parts by weight of a siloxane-co-polyester (E). | 2013-06-20 |
20130158162 | FRICTION MATERIAL - There is provided a friction material. The friction material includes a fibrous material, a friction modifier, and a binder. The friction material contains potassium titanate powders, steel fibers, calcium pyrophosphate and iron oxide. An amount of the potassium titanate powders may be 10 to 30 mass %. An amount of the steel fibers may be 1 to 7 mass %. An amount of the calcium pyrophosphate may be 5 to 20 mass %. An amount of the iron oxide may be 1 to 5 mass %. | 2013-06-20 |
20130158163 | METHOD FOR MANUFACTURING RUBBER COMPOSITION, RUBBER COMPOSITION, AND TIRE USING SAME - The present invention is a method for manufacturing a rubber composition containing a rubber component, a resin, a reinforcing filler and a crosslinking agent, and the method contains: a first step of adding the resin to the rubber component to produce a master batch; a second step of kneading the master batch with the reinforcing filler to produce a filled master batch; and a third step of kneading the filled master batch with the crosslinking agent, thereby providing a rubber composition having higher elasticity and large breaking elongation. | 2013-06-20 |
20130158164 | ELASTOMER COMPOSITE WITH SILICA-CONTAINING FILLER AND METHODS TO PRODUCE SAME - An elastomer composite with silica-containing filler is described, along with methods to make the same. The advantages achieved with the elastomer composite and methods are further described. | 2013-06-20 |
20130158165 | EPOXY RESIN COMPOSITION FOR ENCAPSULATING SEMICONDUCTOR DEVICE AND SEMICONDUCTOR DEVICE ENCAPSULATED WITH THE SAME - An epoxy resin composition for encapsulating a semiconductor device and a semiconductor device encapsulated with the composition, the composition including an epoxy resin; an inorganic filler; a curing accelerator; and a curing agent, the curing agent including a compound having a multifunctional novolac structure including at least one biphenyl moiety, the compound being represented by Formula 1: | 2013-06-20 |
20130158166 | CURABLE EPOXY COMPOSITION WITH QUATERNARY AMMONIUM BICARBONATE CURING CATALYST - Quaternary ammonium bicarbonates are suitable for use as catalysts in curable epoxy compositions. The curable compositions prepared therewith are used to prepare coated substrates, and to produce conformally sealed printed wiring boards and flexible circuits. Methods for preparation and curing are also provided. Of particular utility are compositions comprising benzytrimethyl ammonium bicarbonate. | 2013-06-20 |
20130158167 | CURABLE EPOXY RESIN COMPOSITION AND OPTICAL SEMICONDUCTOR DEVICE USING SAID RESIN COMPOSITION - A curable epoxy resin composition according to the present invention is a curable epoxy resin composition which includes a rubber-particle-dispersed epoxy compound (A) including an alicyclic epoxy compound and, dispersed therein, rubber particles. The curable epoxy resin composition further includes an alumina (B); and an aliphatic polyglycidyl ether (C) having a viscosity of 8000 mPa·s or more at 25° C. The rubber particles include a polymer derived from a (meth)acrylic ester as an essential monomer component, have hydroxyl group and/or carboxyl group on a surface thereof, and have an average particle diameter of 10 nm to 500 nm and a maximum particle diameter of 50 nm to 1000 nm. The curable epoxy resin composition gives a cured product having a refractive index with a difference from the refractive index of the rubber particles of within ±0.03. | 2013-06-20 |
20130158168 | ALIPHATIC-AROMATIC COPOLYETHERESTERS - Provided are aliphatic-aromatic copolyetheresters that can exhibit biodegradation with improved physical properties. The copolyetheresters can be blended with other polymeric materials, and are useful for making a variety of shaped articles. The aliphatic-aromatic copolyetheresters can include combinations of terephthalic acid or ester with linear aliphatic, or a non-linear dicarboxylic acid or ester, that is condensed with a linear glycol and a polyalkylene ether glycol. | 2013-06-20 |
20130158169 | MOLDED ARTICLES OF STARCH-POLYMER-WAX-OIL COMPOSITIONS - Molded articles formed from compositions comprising thermoplastic starch, thermoplastic polymers, and oils, waxes, or combinations thereof are disclosed, where the oil, wax, or combination is dispersed throughout the thermoplastic polymer. | 2013-06-20 |
20130158170 | VULCANIZABLE HALOGENATED ELASTOMER COMPOSITIONS - The invention provides articles obtained from curing a composition consisting of a polymercapto crosslinking agent, a vulcanization accelerator, an inorganic base, a nitrogen containing chelating agent, wherein the nitrogen containing chelating agent is selected from the group consisting of 1,10-phenanthroline and 2,2-bipyridyl, and polyethylenimine; and a halogenated elastomer; wherein said nitrogen containing chelating agent is soluble in said halogenated elastomer. | 2013-06-20 |
20130158171 | PARTICLES COMPRISING COMPOSITE OF PARA-ARAMID AND ADDITIVE MATERIAL - The invention pertains to a method for making a polymer-additive composite particle from a dope by jet spinning the dope to obtain a pulp, fibril or fibrid, wherein the solvent of the dope is selected from N-methyl-2-pyrrolidone, N,N′-dimethylformamide, N,N′-dimethylacetamide, tetramethylurea, and 4 to 75 wt % of a composition consisting of 2 to 95 wt % of a para-aramid polymer and 5-98 wt % of a solid additive material, to a total of 100 wt %, and wherein the aramid polymer is dissolved in the solvent; or coagulating the dope by means of a rotor-stator apparatus in which the polymer solution is applied through the stator on the rotor so that the precipitating polymer-additive composite particle is subjected to shear forces while they are in a plastic deformable stage. | 2013-06-20 |
20130158172 | Tire of which the Tread Comprises a Thermoplastic Vulcanizate (TPV) Elastomer - A tire, the tread of which comprises a rubber composition comprising at least a diene elastomer, such as, for example, an SBR or BR elastomer, a thermoplastic elastomer vulcanizate of EPDM and polypropylene, at a content preferably of greater than 5 phr, and a reinforcing filler, such as silica and/or carbon black. Such a composition confers, on the tire, an improvement in the wet grip. | 2013-06-20 |